| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6723713 | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jan, 2014
(10 years ago) | |
| US5837699 | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jan, 2014
(10 years ago) | |
|
US5837699 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jul, 2014
(9 years ago) | |
|
US6723713 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jul, 2014
(9 years ago) | |
| US6127353 | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Oct, 2017
(6 years ago) | |
|
US6127353 (Pediatric) | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Apr, 2018
(6 years ago) | |
Nasonex is owned by Organon Llc.
Nasonex contains Mometasone Furoate.
Nasonex has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Nasonex are:
- US6723713
- US5837699
- US5837699*PED
- US6723713*PED
- US6127353
- US6127353*PED
Nasonex was authorised for market use on 01 October, 1997.
Nasonex is available in spray, metered;nasal dosage forms.
Nasonex can be used as allergic rhinitis or nasal polyps.
The generics of Nasonex are possible to be released after 03 April, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-99) | Jan 19, 2014 |
| New Indication(I-626) | May 26, 2013 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 01 October, 1997
Treatment: Allergic rhinitis or nasal polyps
Dosage: SPRAY, METERED;NASAL
How can I launch a generic of NASONEX before it's drug patent expiration?
More Information on Dosage
NASONEX family patents
